Clinical trials: Adaptive Trial
Locally Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8
ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy
This phase II trial studies two questions in patients with stage III NSCLC: 1) does it improve cancer control to add the drug Durvalumab, a type of immunotherapy, earlier in the treatment course; and 2) by intensifying treatment…
- Conditions
- Locally Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
- Trial name
- NCT04372927
- Testing
- Cisplatin, Durvalumab, Etoposide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Washington
Cardiac Arrest
Therapeutic Hypothermia to Improve Survival After Cardiac Arrest in Pediatric Patients-THAPCA-IH [In Hospital] Trial
Cardiac arrest is a sudden, unexpected loss of heart function. Therapeutic hypothermia, in which the body's temperature is lowered and maintained several degrees below normal for a period of time, has been used to successfully…
- Trial name
- THAPCA-IH (NCT00880087)
- Testing
- Therapeutic Hypothermia, Therapeutic Normothermia
- Where
- 33 sites in United States, Canada and 1 more
- Volunteers
- 329 people
- Sponsor
- University of Michigan
Sepsis
Vitamin C, Thiamine, and Steroids in Sepsis
The VItamin C, Thiamine And Steroids in Sepsis (VICTAS) Study is a double-blind, placebo-controlled, adaptive randomized clinical trial designed to investigate the efficacy of the combined use of vitamin C, thiamine and…
- Trial name
- VICTAS (NCT03509350)
- Testing
- Vitamin C, Thiamine, Hydrocortisone
- Where
- 43 sites in United States
- Volunteers
- 501 people
- Sponsor
- Emory University
COVID-19
PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
This study looks at the safety and effectiveness of PF-07304814 in treating COVID-19 in people who have been hospitalized with the infection.
- Trial name
- NCT05780541
- Testing
- PF-07304814, Remdesivir
- Where
- 40 sites in United States, Denmark
- Volunteers
- 58 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
SARS-CoV-2
PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19
This study is an adaptive, randomized, double blind, platform trial evaluating promising investigational products (IP) for safety and efficacy as early outpatient treatment and post-exposure prophylaxis for Severe Acute…
- Trial name
- PROTECT-APT 1 (NCT05954286)
- Testing
- Upamostat
- Where
- 6 sites in United States, South Africa and 2 more
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
Procedural Anxiety
Dose-Finding Study of Intranasal Midazolam for Procedural Sedation in Children
Dose-finding study to compare intranasal midazolam doses of 0.2, 0.3, 0.4 and 0.5 mg/kg in children undergoing laceration repair to achieve the following aims: Specific Aim #1: To determine the most effective dose of intranasal…
- Trial name
- NCT04586504
- Testing
- Intranasal midazolam
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Columbia University
Pancreatic Adenocarcinoma, Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
This phase II trial evaluates whether early switching from modified fluorouracil/irinotecan/leucovorin/oxaliplatin (mFOLFIRINOX) chemotherapy regimen to a combination of gemcitabine and nab-paclitaxel (GA) before surgery is…
- Conditions
- Pancreatic Adenocarcinoma, Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8, Stage I Pancreatic Cancer American Joint Committee on Cancer v8, Stage III Pancreatic Cancer American Joint Committee on Cancer v8
- Trial name
- NCT04539808
- Testing
- Capecitabine, Fluorouracil, Irinotecan Hydrochloride
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- OHSU Knight Cancer Institute
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer
Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer
This randomized phase II trial studies how well carboplatin and combination chemotherapy with or without veliparib works in treating patients with stage IIB-IIIC breast cancer.
- Conditions
- Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT01818063
- Testing
- Paclitaxel, Carboplatin, Doxorubicin
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Cardiac Arrest
Therapeutic Hypothermia to Improve Survival After Cardiac Arrest in Pediatric Patients-THAPCA-OH [Out of Hospital] Trial
Cardiac arrest is a sudden, unexpected loss of heart function. Therapeutic hypothermia, in which the body's temperature is lowered and maintained several degrees below normal for a period of time, has been used to successfully…
- Trial name
- THAPCA-OH (NCT00878644)
- Testing
- Therapeutic Hypothermia, Therapeutic Normothermia
- Where
- 34 sites in United States, Canada
- Volunteers
- 295 people
- Sponsor
- University of Michigan
Borderline Personality Disorder
Study to Test the Efficacy and Safety of Vafidemstat in Adult Borderline Personality Disorder Population
PORTICO is a Phase IIb study to evaluate the efficacy and safety of vafidemstat in an adult borderline personality disorder (BPD) population.
- Trial name
- NCT04932291
- Testing
- vafidemstat
- Where
- 21 sites in United States, Bulgaria and 3 more
- Volunteers
- 211 people
- Sponsor
- Oryzon Genomics S.A.
COVID-19
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
A multi-center adaptive randomized placebo-controlled platform trial evaluating the efficacy and safety of anti-thrombotic strategies in COVID-19 adults not requiring hospitalization at time of diagnosis
- Trial name
- NCT04498273
- Testing
- Apixaban 2.5 MG, Apixaban 5MG, Aspirin
- Where
- 71 sites in United States
- Volunteers
- 657 people
- Sponsor
- Frank C Sciurba
Hearing Loss, Sensorineural
Remote Microphone Candidacy Study
Despite improvements in digital hearing aid technology, many hearing aid users continue to report difficulty understanding speech in challenging listening environments.
- Trial name
- NCT03897634
- Testing
- Remote Microphone
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Brain Neoplasms, Central Nervous System Neoplasms
Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma
The goal of Part I of this clinical research study is to find the highest tolerable dose of TPI 287 that can be given with bevacizumab to patients with glioblastoma.
- Trial name
- NCT01582152
- Testing
- TPI287, Bevacizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center
COVID-19
Adaptive COVID-19 Treatment Trial (ACTT)
This study is an adaptive, randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of novel therapeutic agents in hospitalized adults diagnosed with COVID-19.
- Trial name
- NCT04280705
- Testing
- Remdesivir
- Where
- 60 sites in United States, Denmark and 8 more
- Volunteers
- 1,062 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Non-Small-Cell Lung Carcinoma
Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence
The goal of this clinical research study is to learn if, compared with regular x-ray radiation, proton radiation reduces the risk of developing, treatment-related pneumonitis (TRP) or tumor recurrence (the tumor coming back in…
- Trial name
- NCT00915005
- Testing
- Photon Therapy, Proton Therapy, Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 275 people
- Sponsor
- M.D. Anderson Cancer Center
Cocaine-Related Disorders
Developing Adaptive Interventions for Cocaine Cessation and Relapse Prevention
First, the investigators will determine whether Acceptance and Commitment Therapy in combination with Contingency Management increases initial treatment response rates.
- Trial name
- NCT02896712
- Testing
- Acceptance and Commitment Therapy (ACT), Drug Counseling (DC), Contingency Management (CM)
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- The University of Texas Health Science Center, Houston
Acute Respiratory Distress Syndrome
A Study to Test Whether Different Doses of Alteplase Help People With Severe Breathing Problems Because of COVID-19
This is a study in adults with severe breathing problems because of COVID-19. People who are in hospital on breathing support can participate in the study.
- Trial name
- TRISTARDS (NCT04640194)
- Testing
- Standard of care, Alteplase low dose, Alteplase high dose
- Where
- 37 sites in Austria, Belgium and 11 more
- Volunteers
- 104 people
- Sponsor
- Boehringer Ingelheim
Pancreatic Cancer, Stereotactic Body Radiation Therapy
Pilot Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in Combination With GC4419 in Pancreatic Cancer
The purpose of the phase I/II clinical study is to determine the best dose of fractionated stereotactic radiation therapy (SBRT) given either with Avasopasem manganese (GC4419) or placebo to patients who have been diagnosed with…
- Trial name
- NCT03340974
- Testing
- GC4419, Stereotactic Radiation Therapy (SBRT) 50 Gy, Stereotactic Radiation Therapy (SBRT) 55 Gy
- Where
- 6 sites in United States
- Volunteers
- 42 people
- Sponsor
- Galera Therapeutics, Inc.
COVID-19
BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
This study looks at the safety and effectiveness of BRII-196/BRII-198 in treating COVID-19 in people who have been hospitalized with the infection.
- Trial name
- NCT05780424
- Testing
- BRII-196, BRII-198, Remdesivir
- Where
- 107 sites in United States, Denmark and 6 more
- Volunteers
- 353 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
Adaptive COVID-19 Treatment Trial 3 (ACTT-3)
ACTT-3 will evaluate the combination of interferon beta-1a and remdesivir compared to remdesivir alone. Subjects will be assessed daily while hospitalized.
- Trial name
- NCT04492475
- Testing
- Interferon beta-1a, Remdesivir
- Where
- 64 sites in United States, Japan and 3 more
- Volunteers
- 969 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)